Mometasone/olopatadine - Glenmark Pharmaceuticals

Drug Profile

Mometasone/olopatadine - Glenmark Pharmaceuticals

Alternative Names: GSP 301-1 NS; GSP 301-2 NS; GSP-301; Olopatadine/mometasone; Ryaltris

Latest Information Update: 04 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Anti-inflammatories; Antiallergics; Antihistamines; Dibenzoxepins; Glucocorticoids; Pregnadienediols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Histamine H1 receptor antagonists; Leukotriene B4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Perennial allergic rhinitis; Seasonal allergic rhinitis

Most Recent Events

  • 04 Jan 2018 Chemical structure information added
  • 13 Dec 2017 Safety and efficacy data from a phase III trial in Perennial allergic rhinitis released by Ghenmark
  • 23 Oct 2017 Glenmark announces intention to submit NDA to US FDA for Seasonal and Perennial allergic rhinitis in 2018 (9227636; 9225033)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top